Skip to main content
. 2024 Sep 15;14(9):4459–4471. doi: 10.62347/CWOS3653

Figure 4.

Figure 4

External validation of the Nomogram model for progression to CRPC in patients with osseous metastatic PCa and high tumor burden (HTB). A. ROC curve analysis for Nomogram in predicting 1-year and 2-year risk of progression to CRPC in patients with osseous metastatic PCa and HTB using validation group data; B. Decision curve analysis for Nomogram in predicting the 1-year risk of progression to CRPC in patients with HTB and osseous metastatic PCa using validation group data; C. Decision curve analysis for Nomogram in predicting the 2-year risk of progression to CRPC in patients with HTB and osseous metastatic PCa using validation group data; D. Calibration curve of the Nomogram model to predict the 1-year and 2-year progression probability to CRPC in patients with HTB and osseous metastatic PCa. Note: PCa: Prostate cancer, HTB: high tumor burden, CRPC: castration-resistant prostate cancer, DCA: decision curve analysis.